KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Regeneron Pharmaceuticals (REGN) Equity Ratio (2009 - 2026)

Regeneron Pharmaceuticals' quarterly Equity Ratio came in at 0.77 in Q1 2026, down 1.77% year-on-year from 0.78 in Q1 2025, and little changed quarter-over-quarter from 0.77 in Q4 2025.

Regeneron Pharmaceuticals has reported Equity Ratio for 18 years, with the latest figure at 0.77 in Q1 2026.

  • For the quarter ending Q1 2026, Equity Ratio fell 1.77% year-over-year to 0.77; the trailing twelve-month figure through Mar 2026 stood at 0.77 (down 1.77% YoY), and the FY2025 full-year result was 0.77, down 0.87% from the prior year.
  • Equity Ratio for Q1 2026 stood at 0.77, roughly flat from 0.77 in the prior quarter.
  • The five-year high for Equity Ratio was 0.79 in Q1 2024, with the low at 0.76 in Q1 2022.
  • Average Equity Ratio over 5 years is 0.78, with a median of 0.78 recorded in 2024.
  • Year-over-year, Equity Ratio advanced 12.15% in 2022 and fell 1.77% in 2026.
  • Tracing REGN's Equity Ratio over 5 years: stood at 0.78 in 2022, then rose by 1.21% to 0.79 in 2023, then retreated by 0.99% to 0.78 in 2024, then retreated by 0.87% to 0.77 in 2025, then slipped by 0.23% to 0.77 in 2026.
  • The last three Equity Ratio figures came in at 0.77 (Q1 2026), 0.77 (Q4 2025), and 0.77 (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Equity Ratio (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - 0.04
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn -
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - 0.42
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn 0.73
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn 0.77
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn 0.21
10 Revolution Medicines 32.39 Bn 32.39 Bn - 0.67

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 0.77
Dec 31, 2025 0.77
Sep 30, 2025 0.77
Jun 30, 2025 0.78
Mar 31, 2025 0.78
Dec 31, 2024 0.78
Sep 30, 2024 0.78
Jun 30, 2024 0.78
Mar 31, 2024 0.79
Dec 31, 2023 0.79
Sep 30, 2023 0.77
Jun 30, 2023 0.78
Mar 31, 2023 0.78
Dec 31, 2022 0.78
Sep 30, 2022 0.77
Jun 30, 2022 0.76
Mar 31, 2022 0.76
Dec 31, 2021 0.74
Sep 30, 2021 0.73
Jun 30, 2021 0.70
Mar 31, 2021 0.67
Dec 31, 2020 0.64
Sep 30, 2020 0.63
Jun 30, 2020 0.63
Mar 31, 2020 0.77
Dec 31, 2019 0.75
Sep 30, 2019 0.75
Jun 30, 2019 0.74
Mar 31, 2019 0.73
Dec 31, 2018 0.75
Sep 30, 2018 0.73
Jun 30, 2018 0.72
Mar 31, 2018 0.70
Dec 31, 2017 0.70
Sep 30, 2017 0.70
Jun 30, 2017 0.68
Mar 31, 2017 0.62
Dec 31, 2016 0.64
Sep 30, 2016 0.66
Jun 30, 2016 0.66
Mar 31, 2016 0.64
Dec 31, 2015 0.65
Sep 30, 2015 0.64
Jun 30, 2015 0.74
Mar 31, 2015 0.71
Dec 31, 2014 0.66
Sep 30, 2014 0.68
Jun 30, 2014 0.69
Mar 31, 2014 0.68
Dec 31, 2013 0.67
Sep 30, 2013 0.64
Jun 30, 2013 0.63
Mar 31, 2013 0.62
Dec 31, 2012 0.60
Sep 30, 2012 0.49
Jun 30, 2012 0.41
Mar 31, 2012 -0.02
Dec 31, 2011 0.37
Sep 30, 2011 0.44
Jun 30, 2011 0.46
Mar 31, 2011 0.48
Dec 31, 2010 0.48
Sep 30, 2010 0.37
Jun 30, 2010 0.47
Dec 31, 2009 0.54